This is a preview of subscription content, log in via an institution to check access.
References
Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395-406.
Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch Randomized Phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763-73.
Mokdad AA, Minter RM, Zhu H, Augustine MM, Porembka MR, Wang SC, et al. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol. 2017;35(5):515-22.
da Costa WL Jr., Tran Cao HS, Sheetz KH, Gu X, Norton EC, Massarweh NN. Comparative effectiveness of neoadjuvant therapy and upfront resection for patients with resectable pancreatic adenocarcinoma: an instrumental variable analysis. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-09327-3.
da Costa WL Jr, Tran Cao HS, Massarweh NN. Neoadjuvant treatment for patients with localized pancreatic adenocarcinoma: are we there yet? JAMA Oncol. 2020;6(8):1163-4.
Funding
This work was funded by a Research Training Award for Cancer Prevention Post-Graduate Training Program in Integrative Epidemiology from the Cancer Prevention & Research Institute of Texas, grant number RP160097 (Principal Investigator: M. Spitz). It was also supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, and the Center for Innovations in Quality, Effectiveness and Safety (CIN 13-413). The funding body played no part in the design and/or general conduct of this study, had no access to the data or role in data collection, management, analysis, or interpretation, and had no role in preparation, review, or approval of the manuscript.
Author information
Authors and Affiliations
Contributions
All authors provided substantial contributions to the design of the work, and to the analysis, or interpretation of data. All authors revised the manuscript, approved its final version, and agree to be accountable for all aspects of the work.
Corresponding author
Ethics declarations
Disclosure
Wilson Luiz da Costa Jr and Nader N. Massarweh have no conflicts of interest to report.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
da Costa, W.L., Massarweh, N.N. ASO Author Reflections: Multimodality Therapy for Patients with Pancreatic Cancer: Neoadjuvant Therapy for All?. Ann Surg Oncol 28, 3196–3197 (2021). https://doi.org/10.1245/s10434-020-09376-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-020-09376-8